JINGFENG PHARMACEUTI(000908.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
JINGFENG PHARMACEUTI
000908.SZ
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company’s principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the fields of cardiovascular disease, orthopedic pain disease, tumor disease, women and children.
3.120 T
000908.SZMarket value -Rank by Market Cap -/-

Financial Score

21/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking192/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-264.36%E
    • Profit Margin39.82%A
    • Gross Margin62.97%A
  • Growth ScoreC
    • Revenue YoY-1.15%D
    • Net Profit YoY162.76%A
    • Total Assets YoY-14.27%E
    • Net Assets YoY85.50%A
  • Cash ScoreC
    • Cash Flow Margin251.14%C
    • OCF YoY-1.15%D
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreE
    • Gearing Ratio104.30%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges

    ProImmune Ltd has announced the Mastering Immunity 2026 symposium, set for April 13-14, 2026, at the Oriental Riverside Hotel in Shanghai. This inaugural event will focus on immunogenicity challenges in drug development, featuring global leaders in biotherapeutics and regulatory authorities. The symposium aims to provide practical guidance for managing immunogenicity risks, which can significantly impact the success of drug programs. Notable speakers include experts from the FDA, Pfizer, and Roche. The event is positioned as essential for those involved in the biopharmaceutical industry in China.

    MorningStar·
    MorningStar·

    U.S. Stock Movement Update: Anteris Tech surges 41.74%, Corvus Pharma drops 10.09% attracting attention

    In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology stocks and the biopharmaceutical sector performing particularly well. The strong rise of Anteris Tech Global has attracted a significant inflow of funds, while Corvus Pharma has faced notable selling pressure, indicating a polarization of market sentiment. Short-term enthusiasm has increased among small-cap stocks, especially with active performances from individual stocks like Moolec Science and Senmiao Tech, driving fluctuations in related sectors. Overall, the market pace is relatively fast, with funds frequently switching between different themes, leading to increased volatility. The stock with the largest movement in the past hour, Anteris Tech Global, surged by 41.74%, becoming the market's focal point. The stock quickly rose after the opening, attracting a large amount of short-term funds, with sentiment high, seemingly indicating an optimistic outlook for its future prospects. Strong stocks include: 1. Moolec Science SA: up 9.11%, driven by recent market expectations for its new products, with active short-term funds. 2. Senmiao Tech: up 7.75%, performing well against the backdrop of an overall recovery in technology stocks, attracting considerable investor attention. 3. Rezolve AI: up 7.61%, with the company's recent technological advancements igniting market enthusiasm and noticeable fund inflows

    Tracking Unusual Activity·
    US
    BIDU
    +8.05%
    Tracking Unusual Activity·
    US
    BIDU
    +8.05%

    In the Hong Kong stock market, the Hang Seng Index fell 39 points in the first half of the day, Anta dropped over 5%, and SMIC HUA HONG SEMI rose

    The Hong Kong stock market opened softly, with the Hang Seng Index down 39 points at 26,447 points. The National Index fell 24 points, while the Hang Seng Tech Index rose 8 points. The total turnover was HKD 127.653 billion. Anta dropped over 5%, while SMIC rose 4.7%. Baidu's stock price increased by 3.3% due to a target price adjustment. Technology stocks showed mixed performance, with Tencent slightly down 0.2% and Alibaba up 1.1%. In the automotive sector, BYD rose 1.1%

    AASTOCKS·
    HK
    01347
    +5.17%
    HK
    00HSI
    +0.37%
    HK
    09888
    +3.29%
    AASTOCKS·
    HK
    01347
    +5.17%
    HK
    00HSI
    +0.37%
    HK
    09888
    +3.29%

    In the Hong Kong stock market, the Hang Seng Index fell 11 points in the first half of the day, while POP MART rose over 8%, with consumer stocks showing an upward trend

    The Hong Kong stock market fluctuated in the early session, with the Hang Seng Index opening down 19 points, rising a maximum of 74 points before retreating, ultimately closing down 11 points at 26,552 points. The National Index and the Hang Seng Tech Index fell by 11 points and 38 points, respectively. The total turnover was HKD 129.845 billion. Technology stocks generally declined, with Tencent, Baidu, Alibaba, and others all experiencing drops, while only JD.com and Bilibili saw slight increases. Consumer stocks performed relatively strongly, with POP MART rising over 8%

    AASTOCKS·
    HK
    09992
    -1.42%
    AASTOCKS·
    HK
    09992
    -1.42%

    Hong Kong stocks fell 281 points, Alibaba dropped 4%, biotech stocks were sold off, and Li Ning rose 3% against the trend. Experts: The upward wave at the beginning of the year has ended | Hong Kong stock market closing

    The Hong Kong stock market closed down 281 points today, reporting at 26,563 points, marking a three-day decline, with a turnover of HKD 225.6 billion. Alibaba fell by 4%, and biotechnology stocks performed poorly, with both the Hang Seng Index and the Tech Index also declining. Despite the A-shares stabilizing after the release of mainland economic data, the Hong Kong stock market remains in an adjustment phase, with a short-term support level expected at 26,000 points. LI NING rose by 3% against the trend

    Stheadline·
    US
    BABA
    +4.23%
    HK
    09988
    +2.19%
    HK
    02331
    -2.70%
    Stheadline·
    US
    BABA
    +4.23%
    HK
    09988
    +2.19%
    HK
    02331
    -2.70%
    © 2026 Longbridge｜Disclaimer